Logo Eclevar

Eclevar MedTech and RegenLab entered into an agreement to conduct all upcoming PMCF studies for chronic diabetic foot ulcer devices

Paris, October 03, 2024 – Eclevar MedTech, a leading european contract research organization (CRO) specializing in medical devices, proudly announces its colleboration with by RegenLab (swiss manufacturer of medical device) to lead their upcoming clinical studies on their innovative medical devices in wound care. This partnership marks a crucial step in the collaboration between the two companies, aiming to enhance innovation and make products of RegenLab compliant to the european requirement of the MDR 745/2017.

RegenLab, a global leader in manufacturing medical devices for autologous cell therapy, chose Eclevar Medtech for its proven expertise in managing complex clinical trials and its mastery of the stringent regulations of the medical device industry. Founded in 2003 and based in Mont-sur-Lausanne, Switzerland, RegenLab is renowned for its advanced technologies in preparing Platelet-Rich Plasma (PRP) and combined therapies, such as integrating hyaluronic acid.

Logo Eclevar

Eclevar MedTech, located in Paris, has quickly established itself since its founding in 2018 thanks to its integrated approach to clinical trials, from pre-commercialization phases to post-market clinical follow-up (PMCF). Eclevar stands out for its ability to provide tech-enabled service tailored medtech industry to overcome clinical challenges related to the MDR 2017/745, leveraging an international team of experts, clinical trial platform that speeds site feasability and qualification, patients identification as well as state of the Art eCOA/ePRO platform. ECLEVAR MEDTECH is backed by healthtech financial capital such as keles and ballas invest. https://keles.care/

Eclevar designs and conducts innovative and efficient clinical studies by leveraging cutting-edge technologies while ensuring flexibility through its MILO Studio platform. This approach ensures seamless global clinical study management, a particularly relevant asset for partners like RegenLab.

 


Antoine Turzi, Chief Executive Officer of RegenLab: “I am delighted with this collaboration with Eclevar MedTech, a company recognized for its expertise and commitment to excellence in clinical trial management. The quality of medical devices and innovation are at the heart of our business, and it was essential to find a partner capable of meeting the rigorous demands of our projects. Eclevar, with its tailor-made approach and advanced Milo Studio platform, represents a major strategic asset for the success of our future studies. Together, we will not only strengthen regenerative medicine but also improve the quality of life for our patients worldwide.”

 


Chems Hachani, Executive President, Eclevar MedTech: “Working with RegenLab is an extraordinary opportunity. Their commitment to quality and innovation perfectly aligns with our mission to provide high-level clinical and regulatory solutions. We are excited to contribute to their future success and to advance the regenerative health sector together.”

This strategic collaboration between RegenLab and Eclevar MedTech promises to bring significant advancements in the development of new treatments and improve the lives of patients via clinical trials in wound care and related to Platelet-Rich Plasma (PRP) and combined therapies, such as integrating hyaluronic acid.

Press Contacts:

RegenLab  

Communications Service

Email: info@regenlab.com

Website: www.regenlab.com

Eclevar MedTech  

Public Relations Service

Email: Clientcare@eclevar.com

Website: www.eclevarmedtech.com

About RegenLab:

RegenLab is a global leader in the field of medical devices for autologous regenerative medicine. Since 2003, RegenLab has been innovating in designing therapeutic solutions based on PRP and combined therapies for various medical fields. Based in Mont-sur-Lausanne, Switzerland, RegenLab operates in over 160 countries and has treated more than 2 million patients to date.

About Eclevar MedTech:

Eclevar MedTech is a contract research organization (CRO) based in Paris, offering comprehensive services for clinical trials and regulatory compliance in the medical device and in vitro diagnostics sectors. Eclevar designs and conducts innovative and efficient clinical studies using advanced technologies while ensuring flexibility with its MILO Studio platform.

Company identification : Eclevar Medtech UK LTD, 15964075, 124-128 City Road, London, England, EC1V 2NX

Our latest news

Newsletter

Our latest webinar

Our latest whitepaper

Get your copy of our new whitepaper today!